2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycystic Ovary Syndrome
152
Breast Neoplasms
40
Prostatic Neoplasms
31
Insulin Resistance
30
Obesity
23
Neoplasms
16
Endometrial Neoplasms
15
Pancreatic Neoplasms
14
Infertility
14
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
12
Anovulation
10
Lung Neoplasms
9
Neoplasm Metastasis
8
Hyperandrogenism
8
Glioblastoma
8
Diabetes Mellitus
8
Squamous Cell Carcinoma of Head and Neck
7
Metabolic Syndrome
7
Melanoma
7
Rectal Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Head and Neck Neoplasms
5
Diabetes Mellitus, Type 2
5
Brain Neoplasms
5
Adenocarcinoma
5
Weight Loss
4
Uterine Cervical Neoplasms
4
Interventions
Ribavirin
4
ledipasvir
3
peginterferon alfa-2a
2
ledipasvir, sofosbuvir drug combination
2
Sofosbuvir
2
sofosbuvir-velpatasvir drug combination
1
daclatasvir
1
Viusid
1
Simeprevir
1
Metformin
1
Introns
1
Dietary Supplements
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis C, Chronic
×
Metformin
×
Clear all
NCT02319200
2017-01-11
METFOVIR
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
11 enrolled